Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07058974 · ClinicalTrials.gov registry record · Phase 1
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
A Phase 1 study of Smokers and Former Smokers, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT07058974: Recruiting Phase 1 study of Smokers and Former Smokers, sponsored by Icahn School of Medicine at Mount Sinai.
NCT07058974 is a Phase 1 study of Smokers and Former Smokers that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 22 participants, below the 58-participant average among 3 other Smokers trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07058974, a Phase 1 study of Smokers and Former Smokers, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.
Primary Outcome
Number and Type of Grade 3/4 Adverse Events per CTCAE Version 5.0. Toxicity will be assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0. Any patient experiencing a Grade 3 or 4 adverse event must hold drug until toxicity returns to grade 0-1. The treating investigator may hold study drug for any duration if the patient is deemed to be experiencing a Grade 1-2 adverse event related to study drug.
Conditions Studied
Interventions
- DRUG lamivudine
- DRUG rapamycin
- BEHAVIORAL Exercise Regimen
- DIETARY_SUPPLEMENT Spermidine
Study Locations (1)
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
What NCT07058974 shows while recruiting
NCT07058974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 58-participant average among 3 other Smokers trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Smokers appearing as the primary indexed condition, and to 4 interventions - of which lamivudine is the first listed.
NCT07058974 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07058974 about?
NCT07058974 is a clinical study titled "A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation". This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.
What is the current status of trial NCT07058974?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2025-08-25. Estimated completion is 2026-07-01.
What conditions does trial NCT07058974 study?
This clinical trial studies the following conditions: Smokers, Former Smokers.
What interventions are being tested in trial NCT07058974?
The interventions under investigation include: lamivudine (DRUG), rapamycin (DRUG), Exercise Regimen (BEHAVIORAL), Spermidine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07058974?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07058974 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smokers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Whole Body Periodic Acceleration on Airway Endothelial Function
COMPLETED · NA
-
Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers
COMPLETED · NA
-
Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI